Logo Logo
Switch Language to German

Siefker-Radtke, A. O.; Mellado, B.; Decaestecker, K.; Burke, J. M.; O'Hagan, A.; Avadhani, A.; Zhong, B.; Santiago-Walker, A.; De Porre, P.; Brookman-May, S. and Garcia-Donas, J. (2016): Ongoing phase 2 study of erdafitinib (JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (M/UR UC) and FGFR gene alterations. In: Annals of Oncology, Vol. 27

Full text not available from 'Open Access LMU'.

Actions (login required)

View Item View Item